Galectin Therapeutics rises as FDA clears path for late-stage liver drug study

Galectin Therapeutics

23/06/2026 15:15

** Shares of Galectin Therapeutics GALT.O jump 9.25% to $3.06
** The biotech firm says it reached an agreement with FDA on main goals for belapectin study in MASH, a liver disease caused by fat buildup that can lead to scarring and high blood pressure in the liver
** Adds that planned late-stage trial will test if belapectin can prevent disease worsening, including serious vein swelling in the food pipe
** FDA accepted study design with blinded scope reviews to ensure consistent results - GALT
** Says trial could support full approval if successful, instead of faster conditional pathway
** Aims to submit study plan in Q3 2026, seeking partners to fund and develop the drug
** Including sessions move, stock down ~26% YTD

 
  
 

 (Reporting by Sahil Pandey in Bengaluru)
 ((Sahil.Pandey@thomsonreuters.com))